A Randomised, Double-blind, Placebo-controlled, Parallel Group, 8-week Treatment Study to Investigate the Safety, Pharmacodynamics, and Effect of the TLR7 Agonist, GSK2245035, on the Allergen-induced Asthmatic Response in Subjects With Mild Allergic Asthma
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs GSK 2245035 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 17 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 6 Jul 2018.
- 18 May 2017 Planned End Date changed from 15 Jun 2018 to 6 Jul 2018.
- 15 May 2017 Planned End Date changed from 15 Dec 2017 to 15 Jun 2018.